<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2026.1755729</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Severe bacterial infection in thalassemia patients: prevalence, predisposing factors, causative organisms and outcomes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Taya</surname>
<given-names>Ruttanaporn</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tantiworawit</surname>
<given-names>Adisak</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1805733"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thongwitokomarn</surname>
<given-names>Harit</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Srichairatanakool</surname>
<given-names>Sirichai</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Punnachet</surname>
<given-names>Teerachat</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hantrakun</surname>
<given-names>Nonthakorn</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2681402"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Piriyakhuntorn</surname>
<given-names>Pokpong</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2231348"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rattanathammethee</surname>
<given-names>Thanawat</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hantrakool</surname>
<given-names>Sasinee</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chai-Adisaksopha</surname>
<given-names>Chatree</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rattarittamrong</surname>
<given-names>Ekarat</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1657995"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Norasetthada</surname>
<given-names>Lalita</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niprapan</surname>
<given-names>Piangrawee</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2513920"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fanhchaksai</surname>
<given-names>Kanda</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Charoenkwan</surname>
<given-names>Pimlak</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Internal Medicine, Faculty of Medicine, Chiang Mai University</institution>, <city>Chiang Mai</city>, <country country="th">Thailand</country></aff>
<aff id="aff2"><label>2</label><institution>Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University</institution>, <city>Chiang Mai</city>, <country country="th">Thailand</country></aff>
<aff id="aff3"><label>3</label><institution>Division of Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University</institution>, <city>Chiang Mai</city>, <country country="th">Thailand</country></aff>
<aff id="aff4"><label>4</label><institution>Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chiang Mai University</institution>, <city>Chiang Mai</city>, <country country="th">Thailand</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Adisak Tantiworawit, <email xlink:href="mailto:adisak.tan@cmu.ac.th">adisak.tan@cmu.ac.th</email>; <email xlink:href="mailto:atantiwo@yahoo.com">atantiwo@yahoo.com</email></corresp>
<fn fn-type="other" id="fn0001">
<label>&#x2020;</label>
<p>ORCID: Adisak Tantiworawit, <uri xlink:href="https://orcid.org/0000-0002-2381-9292">orcid.org/0000-0002-2381-9292</uri></p>
</fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-18">
<day>18</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>13</volume>
<elocation-id>1755729</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>28</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>02</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Taya, Tantiworawit, Thongwitokomarn, Srichairatanakool, Punnachet, Hantrakun, Piriyakhuntorn, Rattanathammethee, Hantrakool, Chai-Adisaksopha, Rattarittamrong, Norasetthada, Niprapan, Fanhchaksai and Charoenkwan.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Taya, Tantiworawit, Thongwitokomarn, Srichairatanakool, Punnachet, Hantrakun, Piriyakhuntorn, Rattanathammethee, Hantrakool, Chai-Adisaksopha, Rattarittamrong, Norasetthada, Niprapan, Fanhchaksai and Charoenkwan</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-18">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>Thalassemia is one of the most common genetic blood disorders globally. Bacterial infections remain a major cause of death among affected patients. To determine prevalence, predisposing factors, causative organism, and outcomes of severe bacterial infection in thalassemia patients.</p>
</sec>
<sec>
<title>Methods</title>
<p>This retrospective study analyzed data from the Thalassemia Registry of the Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University (September 2013&#x2013;September 2023). Thalassemia patients aged &#x003E;15&#x202F;years were included. Risk factors for severe bacterial infection were identified using multivariate logistic regression. Severe bacterial infection was defined as community-acquired involving a major organ, requiring parenteral antibiotics and/or surgery, and associated with a National Early Warning Score (NEWS)&#x202F;&#x003E;&#x202F;4.</p>
</sec>
<sec>
<title>Results</title>
<p>A total of 208 patients were enrolled (mean age 45.3&#x202F;&#x00B1;&#x202F;16.0&#x202F;years; 62.0% female; 56.7% transfusion-dependent; 36.1% splenectomy). Severe bacterial infection occurred in 43 patients (20.7%). Primary bacteremia was the most common (23.2%), with <italic>Klebsiella pneumoniae</italic> (20.9%) and <italic>Escherichia coli</italic> (13.9%) as the leading pathogens. Infection-related mortality rate was 9.3%. Significant risk factors included hematocrit &#x003C;21% (OR&#x202F;=&#x202F;3.15; 95% CI 1.32&#x2013;7.50; <italic>p</italic>&#x202F;=&#x202F;0.01), splenectomy &#x003E;10&#x202F;years (OR&#x202F;=&#x202F;2.46; 95% CI 1.07&#x2013;5.69; <italic>p</italic>&#x202F;=&#x202F;0.035), diabetes mellitus (OR&#x202F;=&#x202F;10.42; 95% CI 2.21&#x2013;49.12; <italic>p</italic>&#x202F;=&#x202F;0.03), and liver hemochromatosis (OR&#x202F;=&#x202F;3.76; 95% CI 1.64&#x2013;8.63; <italic>p</italic>&#x202F;=&#x202F;0.002).</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Severe bacterial infections affected 20.7% of thalassemia patients in this cohort, mainly bacteremia due to <italic>Klebsiella pneumoniae</italic> and <italic>Escherichia coli.</italic> Major risk factors were severe anemia, prolonged splenectomy, diabetes mellitus, and iron overload with liver hemochromatosis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>anemia</kwd>
<kwd>bacterial infections</kwd>
<kwd>
<italic>Escherichia coli</italic>
</kwd>
<kwd>
<italic>Klebsiella pneumoniae</italic>
</kwd>
<kwd>thalassemia</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="1"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="29"/>
<page-count count="7"/>
<word-count count="4443"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Hematology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<title>Introduction</title>
<p>Thalassemia is an inherited anemia that is highly prevalent in northern Thailand with alpha thalassemia being the most common subtype. Bacterial infection is a major cause of death among patients with thalassemia (<xref ref-type="bibr" rid="ref1 ref2 ref3">1&#x2013;3</xref>). Factors contributing to infection include iron overload, continuous alloantigen stimulation from multiple blood transfusions, zinc deficiency, and reduced immune clearance capacity following splenectomy (<xref ref-type="bibr" rid="ref4 ref5 ref6">4&#x2013;6</xref>).</p>
<p>Severe infections are a major complication in patients with thalassemia, resulting from multiple interacting risk factors (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref8">8</xref>). Iron overload secondary to repeated blood transfusions impairs immune cell function and promotes bacterial proliferation (<xref ref-type="bibr" rid="ref9">9</xref>). Splenomegaly and hypersplenism lead to increased destruction of white blood cells, while splenectomy removes a critical immune organ, predisposing patients to infections caused by encapsulated organisms (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref11">11</xref>). Chronic anemia and malnutrition further compromise host immunity (<xref ref-type="bibr" rid="ref12">12</xref>). In addition, frequent hospital visits and transfusions increase exposure to healthcare-associated pathogens (<xref ref-type="bibr" rid="ref13">13</xref>). Collectively, these factors render patients with thalassemia significantly more susceptible to serious bacterial infections than the general population (<xref ref-type="bibr" rid="ref13">13</xref>).</p>
<p>Previous studies have reported bacterial infections in thalassemia patients caused predominantly by <italic>Escherichia coli</italic>, and <italic>Klebsiella pneumoniae</italic> (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref14 ref15 ref16">14&#x2013;16</xref>). <italic>Burkholderia pseudomallei</italic> has also been identified as a pathogen in the Northeastern region of Thailand (<xref ref-type="bibr" rid="ref14">14</xref>). Septicemia is the most common severe infectious complication (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref15">15</xref>). Evaluated serum ferritin levels, a rapid decline in hemoglobin of more than 2&#x202F;g/dL per week, diabetes mellitus, and a history of splenectomy have been identified as a risk factors associated with increased mortality (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref15">15</xref>).</p>
<p>Most previous studies have focused on individual thalassemia subtypes, with limited comprehensive analyses encompassing all variants. This gap is especially evident in alpha thalassemia patients, where data remain particularly limited. Moreover, the definitions of bacterial infection vary across studies, and the risk factors contributing to severe bacterial infections in thalassemia patients have not been fully elucidated. Therefore, this study aims to investigate both alpha and beta thalassemia patients, with a specific focus on severe bacterial infection.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<title>Materials and methods</title>
<sec id="sec3">
<title>Ethical approval</title>
<p>The study was consisted with the 1975 Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects. The study was approved by the Institutional Research Ethics Committee at the Faculty of Medicine, Chiang Mai University (Study approved number: MED-2566-0202). Informed consent was waived as the study involved no more than minimal risk.</p>
<p>Data were retrospective reviewed from the Thalassemia Registry and medical records of the Division of Hematology, Faculty of Medicine, Chiang Mai University, covering the period from September 2013 to September 2023. Collected data included clinical characteristics, infection site, causative organisms, and clinical outcomes. Baseline laboratory parameters prior to infection were obtained, including completed blood count (CBC), serum ferritin, liver iron concentration (LIC), and cardiac MRI T2&#x002A;.</p>
<p>Severe infection was defined as a community-acquired bacterial infection involving a major organ and requiring parenteral antibiotics administration and/or surgical intervention, with a National Early Warning Score (NEWS) greater than 4 (<xref ref-type="bibr" rid="ref17">17</xref>). The diagnosis was based on the clinical presentation, physical examination findings, and laboratory investigations confirmed by pathogen isolation from blood, pus, stool, cerebrospinal fluid or other body fluids (including negative culture with clinical evidence), as well as imaging studies. Baseline laboratory values were calculated as the mean of five routine blood tests collected before the onset of infection.</p>
<p>For incidence analysis, severe bacterial infection was assessed on a per-patient basis. Only the first episode of severe infection in each patient was included, and recurrent episodes were not counted separately.</p>
</sec>
<sec id="sec4">
<title>Patients</title>
<p>Eligibility participants included patients who diagnosed with thalassemia both alpha and beta subtypes confirmed by high-performance liquid chromatography (HPLC) and molecular testing, aged over 15&#x202F;years. Patients with other risk factors for bacterial infection, such as HIV infection, malignancy, other hemolytic diseases or those receiving immunosuppressive therapy, were excluded.</p>
</sec>
<sec id="sec5">
<title>Outcomes</title>
<p>The primary endpoints of the study were the prevalence, causative organisms, sources of infection, and risk factors associated with severe bacterial infections. The secondary endpoint was the clinical outcome of severe bacterial infections, categorized as a recovery without intensive care unit (ICU) admission, recovery with ICU admission, or death.</p>
</sec>
<sec id="sec6">
<title>Statistical analysis</title>
<p>According to a previous study (<xref ref-type="bibr" rid="ref16">16</xref>), the incidence of severe bacterial infection among transfusion-dependent thalassemia patients was 22.47%. With an allocation ratio of 3.5, a 95% confidence intervals (CI), and a test power of 80%, the required sample size was calculated to be 230.</p>
<p>Continuous variables with normally distribution were presented as mean, and standard deviation (SD), while those with a non -normal distribution were presented as median and interquartile range (IQR). Categorical variables were reported as percentages. Univariable logistic regression was first used to identify potential risk factors for severe bacterial infections, followed by multivariable logistic regression. Risk factors were presented as adjusted odds ratios (OR) with 95% CI. The prevalence, causative organisms, and infection sites were also described. Statistical significance was defined as <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05. All statistical analyses were performed using STATA software, version 10 (StataCorp, College Station, TX, USA).</p>
</sec>
</sec>
<sec sec-type="results" id="sec7">
<title>Results</title>
<p>A total of 247 patients with thalassemia were enrolled in the study. Thirty-nine patients were excluded due to HIV infection, malignancy, immunosuppressive therapy, or other hemolytic diseases. A total of 208 patients with thalassemia were included, comprising 144 patients with beta-thalassemia and 64 patients with alpha-thalassemia.</p>
<p>Severe bacterial infections were identified in 43 of the remaining 208 patients, resulting in a prevalence rate of 20.7%. The prevalence of severe bacterial infection was 22.2% (32/144) in patients with beta-thalassemia and 17.2% (11/64) in those with alpha-thalassemia. Although patients with beta-thalassemia had a slightly higher incidence of severe bacterial infection compared with those with alpha-thalassemia, the difference was not statistically significant (<italic>p</italic> value&#x202F;=&#x202F;0.408). The clinical characteristics of the study population are summarized in <xref ref-type="table" rid="tab1">Table 1</xref>. The mean age in both infected and non-infected groups was 45&#x202F;years, with a higher proportion of female patients. Diabetes mellitus and pulmonary hypertension were more frequent complications observed in the infected group. Beta-thalassemia/HbE disease was the most common subtype among all participants and was also the most predominant subtype in the infected group. Baseline hemoglobin levels were slightly lower in the infected group compared to the non-infected group, with a similar trend observed for hematocrit levels. Conversely, serum ferritin levels were higher in the infected group. Deferiprone was the most frequently used iron chelating agent, while the combination of deferoxamine and deferiprone was the most common dual iron chelating regimen, accounting for 17.6% of patients. Liver hemochromatosis was the most frequent site of iron overload, followed by involvement of the endocrine system.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Clinical characteristics of thalassemia patients with severe bacterial infection.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Characteristics</th>
<th align="center" valign="top">Total (<italic>n</italic> =&#x202F;208)</th>
<th align="center" valign="top">No infection (<italic>n</italic> =&#x202F;165)</th>
<th align="center" valign="top">Infection (<italic>n</italic> =&#x202F;43)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Age at enrollment, years, mean &#x00B1; SD</td>
<td align="center" valign="top">45.3&#x202F;&#x00B1;&#x202F;16.0</td>
<td align="center" valign="top">45.6&#x202F;&#x00B1;&#x202F;16.9</td>
<td align="center" valign="top">44.2&#x202F;&#x00B1;&#x202F;12.2</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Sex, <italic>n</italic> (%)</td>
</tr>
<tr>
<td align="left" valign="top">Female</td>
<td align="center" valign="top">129 (62.0)</td>
<td align="center" valign="top">103 (62.4)</td>
<td align="center" valign="top">26 (60.5)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Underlying disease, <italic>n</italic> (%)</td>
</tr>
<tr>
<td align="left" valign="top">Hypertension</td>
<td align="center" valign="top">15 (7.2)</td>
<td align="center" valign="top">14 (8.5)</td>
<td align="center" valign="top">1 (2.3)</td>
</tr>
<tr>
<td align="left" valign="top">Diabetes mellitus</td>
<td align="center" valign="top">23 (11.1)</td>
<td align="center" valign="top">16 (9.7)</td>
<td align="center" valign="top">7 (16.3)</td>
</tr>
<tr>
<td align="left" valign="top">Heart failure</td>
<td align="center" valign="top">3 (1.4)</td>
<td align="center" valign="top">2 (1.2)</td>
<td align="center" valign="top">1 (2.3)</td>
</tr>
<tr>
<td align="left" valign="top">Pulmonary hypertension</td>
<td align="center" valign="top">17 (8.2)</td>
<td align="center" valign="top">10 (6.1)</td>
<td align="center" valign="top">7 (16.3)</td>
</tr>
<tr>
<td align="left" valign="top">HBV/HCV infection</td>
<td align="center" valign="top">16 (7.7)</td>
<td align="center" valign="top">13 (7.9)</td>
<td align="center" valign="top">3 (7.0)</td>
</tr>
<tr>
<td align="left" valign="top">Liver cirrhosis</td>
<td align="center" valign="top">6 (2.9)</td>
<td align="center" valign="top">3 (1.8)</td>
<td align="center" valign="top">3 (7.0)</td>
</tr>
<tr>
<td align="left" valign="top">Chronic kidney disease</td>
<td align="center" valign="top">6 (2.9)</td>
<td align="center" valign="top">5 (3.0)</td>
<td align="center" valign="top">1 (2.3)</td>
</tr>
<tr>
<td align="left" valign="top">Osteoporosis</td>
<td align="center" valign="top">46 (22.1)</td>
<td align="center" valign="top">38 (23.0)</td>
<td align="center" valign="top">8 (18.6)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Thalassemia type, <italic>n</italic> (%)</td>
</tr>
<tr>
<td align="left" valign="top">Alpha-thalassemia</td>
<td align="center" valign="top"><bold>64 (30.8)</bold></td>
<td align="center" valign="top"><bold>53 (32.1)</bold></td>
<td align="center" valign="top"><bold>11 (25.6)</bold></td>
</tr>
<tr>
<td align="left" valign="top">HbH disease with variants<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="center" valign="top">52 (81.3)</td>
<td align="center" valign="top">44 (83.0)</td>
<td align="center" valign="top">8 (72.7)</td>
</tr>
<tr>
<td align="left" valign="top">HbH with CS with variants<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></td>
<td align="center" valign="top">12 (18.8)</td>
<td align="center" valign="top">9 (17.0)</td>
<td align="center" valign="top">3 (27.3)</td>
</tr>
<tr>
<td align="left" valign="top">Beta-thalassemia</td>
<td align="center" valign="top"><bold>144 (69.2)</bold></td>
<td align="center" valign="top"><bold>112 (67.9)</bold></td>
<td align="center" valign="top"><bold>32 (74.4)</bold></td>
</tr>
<tr>
<td align="left" valign="top">Beta thalassemia major</td>
<td align="center" valign="top">26 (18.1)</td>
<td align="center" valign="top">18 (16.1)</td>
<td align="center" valign="top">8 (25.0)</td>
</tr>
<tr>
<td align="left" valign="top">Beta thalassemia/HbE disease</td>
<td align="center" valign="top">113 (78.5)</td>
<td align="center" valign="top">90 (80.3)</td>
<td align="center" valign="top">22 (71.9)</td>
</tr>
<tr>
<td align="left" valign="top">Homozygous HbE</td>
<td align="center" valign="top">3 (2.1)</td>
<td align="center" valign="top">2 (1.8)</td>
<td align="center" valign="top">1 (3.1)</td>
</tr>
<tr>
<td align="left" valign="top">Other<xref ref-type="table-fn" rid="tfn3"><sup>c</sup></xref></td>
<td align="center" valign="top">2 (1.3)</td>
<td align="center" valign="top">2 (1.8)</td>
<td align="center" valign="top">0 (0.00)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Baseline laboratory</td>
</tr>
<tr>
<td align="left" valign="top">Hemoglobin (g/dL), mean &#x00B1; SD</td>
<td align="center" valign="top">7.64&#x202F;&#x00B1;&#x202F;1.48</td>
<td align="center" valign="top">7.71&#x202F;&#x00B1;&#x202F;1.51</td>
<td align="center" valign="top">7.36&#x202F;&#x00B1;&#x202F;1.33</td>
</tr>
<tr>
<td align="left" valign="top">Hematocrit (%), mean &#x00B1; SD</td>
<td align="center" valign="top">24.72&#x202F;&#x00B1;&#x202F;5.02</td>
<td align="center" valign="top">25.16&#x202F;&#x00B1;&#x202F;5.01</td>
<td align="center" valign="top">23.04&#x202F;&#x00B1;&#x202F;4.76</td>
</tr>
<tr>
<td align="left" valign="top">White blood cell (&#x00D7;10<sup>9</sup>/L), (IQR)</td>
<td align="center" valign="top">8.05 (6.12, 13.39)</td>
<td align="center" valign="top">7.80 (6.00, 12.63)</td>
<td align="center" valign="top">10.07 (7.05, 14.77)</td>
</tr>
<tr>
<td align="left" valign="top">Platelet (&#x00D7;10<sup>9</sup>/L), (IQR)</td>
<td align="center" valign="top">273.75 (179.25, 533.25)</td>
<td align="center" valign="top">260.50 (179.00, 532.00)</td>
<td align="center" valign="top">369.00 (183.50, 545.50)</td>
</tr>
<tr>
<td align="left" valign="top">Serum ferritin (&#x03BC;g/mL), (IQR)</td>
<td align="center" valign="top">1047.6 (698.8, 2038.7)</td>
<td align="center" valign="top">938.8 (681.0, 1649.4)</td>
<td align="center" valign="top">1660.8 (854.3, 3989.2)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Splenectomy, <italic>n</italic> (%)</td>
</tr>
<tr>
<td align="left" valign="top">Yes</td>
<td align="center" valign="top">75 (36.1)</td>
<td align="center" valign="top">52 (31.5)</td>
<td align="center" valign="top">23 (53.5)</td>
</tr>
<tr>
<td align="left" valign="top">Years after splenectomy, mean &#x00B1; SD</td>
<td align="center" valign="top">25.3&#x202F;&#x00B1;&#x202F;10.1</td>
<td align="center" valign="top">25.0&#x202F;&#x00B1;&#x202F;10.2</td>
<td align="center" valign="top">26.0&#x202F;&#x00B1;&#x202F;10.1</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Iron chelating agent, <italic>n</italic> (%)</td>
</tr>
<tr>
<td align="left" valign="top">Deferoxamine</td>
<td align="center" valign="top">65 (31.3)</td>
<td align="center" valign="top">46 (27.9)</td>
<td align="center" valign="top">19 (44.2)</td>
</tr>
<tr>
<td align="left" valign="top">Deferiprone</td>
<td align="center" valign="top">132 (63.5)</td>
<td align="center" valign="top">104 (63.0)</td>
<td align="center" valign="top">28 (65.1)</td>
</tr>
<tr>
<td align="left" valign="top">Deferasirox</td>
<td align="center" valign="top">36 (17.3)</td>
<td align="center" valign="top">31 (18.8)</td>
<td align="center" valign="top">5 (11.6)</td>
</tr>
<tr>
<td align="left" valign="top">Combine deferoxamine</td>
<td align="center" valign="top">56 (26.9)</td>
<td align="center" valign="top">41 (24.8)</td>
<td align="center" valign="top">15 (34.9)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Secondary hemochromatosis, <italic>n</italic> (%)</td>
</tr>
<tr>
<td align="left" valign="top">Cardiac hemochromatosis</td>
<td align="center" valign="top">3 (1.4)</td>
<td align="center" valign="top">2 (1.2)</td>
<td align="center" valign="top">1 (2.3)</td>
</tr>
<tr>
<td align="left" valign="top">Endocrine</td>
<td align="center" valign="top">54 (26.0)</td>
<td align="center" valign="top">37 (22.4)</td>
<td align="center" valign="top">17 (39.5)</td>
</tr>
<tr>
<td align="left" valign="top">Liver hemochromatosis (LIC&#x202F;&#x2265;&#x202F;7&#x202F;mg/g)</td>
<td align="center" valign="top">69 (33.2)</td>
<td align="center" valign="top">46 (27.9)</td>
<td align="center" valign="top">23 (53.5)</td>
</tr>
<tr>
<td align="left" valign="top">EMH</td>
<td align="center" valign="top">31 (14.9)</td>
<td align="center" valign="top">22 (13.3)</td>
<td align="center" valign="top">9 (20.9)</td>
</tr>
<tr>
<td align="left" valign="top">Cardiac T2&#x002A; (ms), mean &#x00B1; SD</td>
<td align="center" valign="top">39.7&#x202F;&#x00B1;&#x202F;8.2</td>
<td align="center" valign="top">40.7&#x202F;&#x00B1;&#x202F;7.2</td>
<td align="center" valign="top">37.4&#x202F;&#x00B1;&#x202F;9.9</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1">
<label>a</label>
<p>AE Bart&#x2019;s, EH Bart&#x2019;s.</p>
</fn>
<fn id="tfn2">
<label>b</label>
<p>AE Bart&#x2019;s CS, Bart&#x2019;s CS.</p>
</fn>
<fn id="tfn3">
<label>c</label>
<p>Beta thal/Hb Tak, Hb Jax/CS.</p>
</fn>
<p>SD, standard deviation; IQR, interquartile range; HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; LIC, liver iron concentration; EMH, extramedullary hematopoiesis.</p>
</table-wrap-foot>
</table-wrap>
<p>Among the 43 patients with severe infections, unidentified organisms were the most common finding, reported in 18 cases (41.9%). The most frequently identified pathogen was <italic>Klebsiella pneumoniae</italic>, detected in 9 patients (20.9%), followed by <italic>Escherichia coli</italic> in 6 patients (14.0%). Less common pathogens included <italic>Aeromonas species</italic> in 4 cases (9.3%) and <italic>Pseudomonas aeruginosa</italic> in 2 cases (4.7%). Rare infections were caused by <italic>Campylobacter species</italic>, <italic>Neisseria species</italic>, <italic>Streptococcus pyogenes</italic>, and <italic>Staphylococcus aureus</italic>, with each identified in one patient (2.3%). Overall, Gram-negative bacteria were the predominant organisms of severe infections in this cohort. A considerable proportion of infections, particularly those involving the hepatobiliary tract infection (41.9%), had unidentified organisms (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Causative organisms of severe bacterial infection.</p>
</caption>
<graphic xlink:href="fmed-13-1755729-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Horizontal bar chart comparing causative organisms by percentage, with Unidentified organism at about 40 percent, Klebsiella pneumoniae at nearly 20 percent, and all others below 15 percent. Y-axis lists organisms; X-axis is percentage.</alt-text>
</graphic>
</fig>
<p>The distribution of infection sites was as follows; bacteremia (23.2%), hepatobiliary tract (17.9%), genitourinary tract (16.1%), head and neck (12.5%), gastrointestinal tract (8.9%), sepsis of unknown origin (7.1%), respiratory tract (7.1%), skin and soft tissue (5.4%), and bone and joint (1.8%). The mortality rate attributed to bacterial infection was 9.3%.</p>
<p>Significant risk factors for severe bacterial infection are presented in <xref ref-type="table" rid="tab2">Table 2</xref>. On multivariable logistic regression analysis, hematocrit less than 21%, splenectomy duration more than 10&#x202F;years, diabetes mellitus, and liver hemochromatosis were identified as statistically significant predictors of severe infection. There was no significant association between pulmonary hypertension, transfusion-dependent thalassemia, deferoxamine used, and occurrence of severe bacterial infection.</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Univariable and multivariable logistic regression for factors associated with severe bacterial infection in patients with thalassemia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th rowspan="2" align="left" valign="top">Factors</th>
<th align="center" valign="top" colspan="3">Univariable logistic regression</th>
<th align="center" valign="top" colspan="3">Multivariable logistic regression</th>
</tr>
<tr>
<th align="center" valign="top">OR</th>
<th align="center" valign="top">95% CI</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
<th align="center" valign="top">AOR</th>
<th align="center" valign="top">95%CI</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Age at enrollment, years, mean &#x00B1; SD</td>
<td align="char" valign="top" char=".">0.99</td>
<td align="char" valign="top" char="&#x2013;">0.97&#x2013;1.02</td>
<td align="char" valign="top" char=".">0.595</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Female</td>
<td align="char" valign="top" char=".">0.92</td>
<td align="char" valign="top" char="&#x2013;">0.46&#x2013;1.83</td>
<td align="char" valign="top" char=".">0.814</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Pulmonary hypertension</td>
<td align="char" valign="top" char=".">3.01</td>
<td align="char" valign="top" char="&#x2013;">1.07&#x2013;8.46</td>
<td align="char" valign="top" char=".">0.036</td>
<td align="char" valign="top" char=".">1.63</td>
<td align="char" valign="top" char="&#x2013;">0.48&#x2013;5.47</td>
<td align="char" valign="top" char=".">0.435</td>
</tr>
<tr>
<td align="left" valign="top">Transfusion-dependent thalassemia</td>
<td align="char" valign="top" char=".">2.02</td>
<td align="char" valign="top" char="&#x2013;">0.98&#x2013;4.15</td>
<td align="char" valign="top" char=".">0.05</td>
<td align="char" valign="top" char=".">0.82</td>
<td align="char" valign="top" char="&#x2013;">0.31&#x2013;2.19</td>
<td align="char" valign="top" char=".">0.694</td>
</tr>
<tr>
<td align="left" valign="top">Hematocrit &#x2264;21%</td>
<td align="char" valign="top" char=".">2.56</td>
<td align="char" valign="top" char="&#x2013;">1.23&#x2013;5.32</td>
<td align="char" valign="top" char=".">0.012</td>
<td align="char" valign="top" char=".">3.15</td>
<td align="char" valign="top" char="&#x2013;">1.32&#x2013;7.50</td>
<td align="char" valign="top" char="."><bold>0.010</bold></td>
</tr>
<tr>
<td align="left" valign="top">Serum ferritin &#x2265;1,000&#x202F;&#x03BC;g/mL</td>
<td align="char" valign="top" char=".">2.95</td>
<td align="char" valign="top" char="&#x2013;">1.42&#x2013;6.15</td>
<td align="char" valign="top" char=".">0.004</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">History of splenectomy</td>
<td align="char" valign="top" char=".">2.50</td>
<td align="char" valign="top" char="&#x2013;">1.26&#x2013;4.95</td>
<td align="char" valign="top" char=".">0.009</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Splenectomy &#x003E;10&#x202F;years</td>
<td align="char" valign="top" char=".">2.41</td>
<td align="char" valign="top" char="&#x2013;">1.22&#x2013;4.78</td>
<td align="char" valign="top" char=".">0.012</td>
<td align="char" valign="top" char=".">2.46</td>
<td align="char" valign="top" char="&#x2013;">1.07&#x2013;5.69</td>
<td align="char" valign="top" char="."><bold>0.035</bold></td>
</tr>
<tr>
<td align="left" valign="top">Deferoxamine</td>
<td align="char" valign="top" char=".">2.05</td>
<td align="char" valign="top" char="&#x2013;">1.03&#x2013;4.09</td>
<td align="char" valign="top" char=".">0.042</td>
<td align="char" valign="top" char=".">0.78</td>
<td align="char" valign="top" char="&#x2013;">0.31&#x2013;1.98</td>
<td align="char" valign="top" char=".">0.596</td>
</tr>
<tr>
<td align="left" valign="top">Diabetes mellitus</td>
<td align="char" valign="top" char=".">8.75</td>
<td align="char" valign="top" char="&#x2013;">2.09&#x2013;36.64</td>
<td align="char" valign="top" char=".">0.003</td>
<td align="char" valign="top" char=".">10.42</td>
<td align="char" valign="top" char="&#x2013;">2.21&#x2013;49.12</td>
<td align="char" valign="top" char="."><bold>0.003</bold></td>
</tr>
<tr>
<td align="left" valign="top">Liver hemochromatosis/LIC&#x202F;&#x003E;&#x202F;7</td>
<td align="char" valign="top" char=".">2.98</td>
<td align="char" valign="top" char="&#x2013;">1.49&#x2013;5.93</td>
<td align="char" valign="top" char=".">0.002</td>
<td align="char" valign="top" char=".">3.76</td>
<td align="char" valign="top" char="&#x2013;">1.64&#x2013;8.63</td>
<td align="char" valign="top" char="."><bold>0.002</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>OR, odds ratio; AOR, adjusted odds ratio; CI, confidence intervals; LIC, liver iron concentration.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec sec-type="discussion" id="sec8">
<title>Discussion</title>
<p>Bacterial infections have been frequently reported in patients with thalassemia, a condition characterized by several notable immune alterations. These include a reduction in neutrophil count, altered number and function of natural killer (NK) cells, increased CD8+ suppressor T cells activity, and impaired macrophage function. Additionally, abnormalities in chemotaxis and phagocytosis, as well as altered production of interferon-gamma (IFN-&#x03B3;), have been documented, all of which contribute to the increased susceptibility to infections in these patients (<xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref18">18</xref>).</p>
<p>The incidence of infection observed in this cohort was consistent with findings from previous study (<xref ref-type="bibr" rid="ref16">16</xref>). This study included all types of thalassemia. Bacteremia was the most common type of infection, aligning with reports from Northeast Thailand and Taiwan (<xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref16">16</xref>). <italic>Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic> remained the predominant pathogens responsible for bacterial infections in thalassemia patients. However, unlike prior study (<xref ref-type="bibr" rid="ref14">14</xref>), no cases of <italic>Burkholderia pseudomallei</italic> infection were identified in our center, which may be explained by regional epidemiology, as this pathogen is uncommon in our region (<xref ref-type="bibr" rid="ref19">19</xref>). Thalassemia patients exhibit a higher prevalence of gut-associated bacteria that are typically considered detrimental, leading to dysbiosis and increases the susceptibility to infection, particularly those caused by <italic>Enterobacteriaceae</italic> spp. (<xref ref-type="bibr" rid="ref20">20</xref>). Reduced phagocytic activity due to iron overload and liver dysfunction may further predispose patients to <italic>Klebsiella pneumoniae</italic> infection (<xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref21">21</xref>). No association between <italic>Yersinia</italic> infection and deferoxamine therapy was observed in our study, differing from previous reports (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref22">22</xref>). This discrepancy may be explained by the limited use of deferoxamine in our cohort.</p>
<p>In contrast, head and neck infections were more prevalent in our study compared to previous research (13% vs. 5%) (<xref ref-type="bibr" rid="ref23">23</xref>). The primary cause of deep neck infections was odontogenic, accounting for 40% of cases, with dental caries being the most common etiology, often related to poor oral hygiene (<xref ref-type="bibr" rid="ref24">24</xref>). High iron deposition in the salivary glands leads to reduced phosphorus and IgA concentrations in saliva, as well as decreased saliva flow, further contributing to the risk of infection (<xref ref-type="bibr" rid="ref25">25</xref>).</p>
<p>In our study, the significant predisposing factors of severe bacterial infection were lower pre-transfusion hematocrit, diabetes mellitus, splenectomy performed more than 10&#x202F;years prior, and liver hemochromatosis. These findings are consistent with previous reports (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref14">14</xref>).</p>
<p>Hemolysis increases levels of non-transferrin-bound iron, free heme, and heme oxygenase-1 (HO-1), which are associated with immune dysfunction and iron homeostasis dysregulation. Invasive bacteria also require iron for their metabolic and pathogenic processes (<xref ref-type="bibr" rid="ref26">26</xref>, <xref ref-type="bibr" rid="ref27">27</xref>). We used liver hemochromatosis as a marker for iron overload rather than serum ferritin, as ferritin does not accurately reflect tissues iron accumulation. Excess iron not only promotes pathogen growth but also plays a critical role in modulating the immune response of the host. A history of splenectomy, especially more than 10&#x202F;years earlier, is associated with a higher risk of infection with encapsulated bacteria due to impaired antibody response to new antigens, mediated by CD4<sup>+</sup> T-cell dysfunction (<xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref28">28</xref>, <xref ref-type="bibr" rid="ref29">29</xref>). Diabetes mellitus, a recognized complication of iron overload in thalassemia, was also identified as a significant risk factor for severe bacterial infection, consistent with prior findings (<xref ref-type="bibr" rid="ref16">16</xref>). These risk factors may help to identify thalassemia patients at high risk of bacterial infections, allowing early detection and prompt antibiotic treatment to improve clinical outcomes.</p>
<p>The strength of our study lies in the inclusion of both alpha and beta thalassemia, enabling comprehensive analysis of the common type, causative organisms, and risk factors for severe bacterial infection. The proposed mechanisms and risk factors may help identify high-risk patients and guide strategies for infection prevention. However, several limitations should be noted. First, some data were missing for certain patients, including vaccination records. Second, other potential risk factors may not have been captured due to the retrospective nature of the study. Third, patient enrollment was limited by the number of eligible cases available during the study period, which may have slightly reduced the statistical power of the study. Therefore, further prospective studies with larger sample sizes are warranted to better explore those associations. Fourth, although serum ferritin levels were higher among patients with infections, C-reactive protein (CRP) and procalcitonin were not routinely measured in most patients in this cohort. Therefore, these biomarkers could not be analyzed in the present study. Additionally, variables such as time to antibiotic administration, appropriateness of antibiotic therapy, and hospital length of stay, should be included in further analyses to be understand their impact on outcomes.</p>
</sec>
<sec sec-type="conclusions" id="sec9">
<title>Conclusion</title>
<p>Severe bacterial infections occurred in 20.7% of thalassemia patients in this cohort, with <italic>Klebsiella pneumoniae</italic> and <italic>Escherichia coli</italic> being the predominant pathogens, most commonly presenting as bacteremia. The overall mortality rate was 9.3%. Major risk factors identified were severe anemia, prolonged splenectomy, diabetes mellitus, and liver hemochromatosis.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec10">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="sec11">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Institutional Research Ethics Committee at the Faculty of Medicine, Chiang Mai University (Study number: MED-2566-0202). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants&#x2019; legal guardians/next of kin in accordance with the national legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="sec12">
<title>Author contributions</title>
<p>RT: Conceptualization, Methodology, Writing &#x2013; original draft, Investigation. AT: Conceptualization, Methodology, Supervision, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. HT: Writing &#x2013; review &#x0026; editing, Conceptualization. SS: Writing &#x2013; review &#x0026; editing. TP: Writing &#x2013; review &#x0026; editing. NH: Writing &#x2013; review &#x0026; editing. PP: Writing &#x2013; review &#x0026; editing. TR: Writing &#x2013; review &#x0026; editing. SH: Writing &#x2013; review &#x0026; editing. CC-A: Writing &#x2013; review &#x0026; editing. ER: Writing &#x2013; review &#x0026; editing. LN: Writing &#x2013; review &#x0026; editing. PN: Investigation, Methodology, Project administration, Writing &#x2013; review &#x0026; editing. KF: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. PC: Writing &#x2013; review &#x0026; editing.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>I would like to thank Ms. Antika Wongthanee, Former Head of Analytical &#x0026; Statistical data unit, Research Institute for Health Sciences, Chiang Mai University, and Ms. Nuttanun Wongsarikan, Research Unit of Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand for their suggestions regarding the statistical analysis in this study.</p>
</ack>
<sec sec-type="COI-statement" id="sec13">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec14">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec15">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhanya</surname><given-names>R</given-names></name> <name><surname>Sedai</surname><given-names>A</given-names></name> <name><surname>Ankita</surname><given-names>K</given-names></name> <name><surname>Parmar</surname><given-names>L</given-names></name> <name><surname>Agarwal</surname><given-names>RK</given-names></name> <name><surname>Hegde</surname><given-names>S</given-names></name> <etal/></person-group>. <article-title>Life expectancy and risk factors for early death in patients with severe thalassemia syndromes in South India</article-title>. <source>Blood Adv</source>. (<year>2020</year>) <volume>4</volume>:<fpage>1448</fpage>&#x2013;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1182/bloodadvances.2019000760</pub-id></mixed-citation></ref>
<ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tantiworawit</surname><given-names>A</given-names></name> <name><surname>Kamolsripat</surname><given-names>T</given-names></name> <name><surname>Piriyakhuntorn</surname><given-names>P</given-names></name> <name><surname>Rattanathammethee</surname><given-names>T</given-names></name> <name><surname>Hantrakool</surname><given-names>S</given-names></name> <name><surname>Chai-Adisaksopha</surname><given-names>C</given-names></name> <etal/></person-group>. <article-title>Survival and causes of death in patients with alpha and beta-thalassemia in northern Thailand</article-title>. <source>Ann Med</source>. (<year>2024</year>) <volume>56</volume>:<fpage>2338246</fpage>. doi: <pub-id pub-id-type="doi">10.1080/07853890.2024.2338246</pub-id>, <pub-id pub-id-type="pmid">38604224</pub-id></mixed-citation></ref>
<ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teawtrakul</surname><given-names>N</given-names></name> <name><surname>Jetsrisuparb</surname><given-names>A</given-names></name> <name><surname>Pongudom</surname><given-names>S</given-names></name> <name><surname>Sirijerachai</surname><given-names>C</given-names></name> <name><surname>Chansung</surname><given-names>K</given-names></name> <name><surname>Wanitpongpun</surname><given-names>C</given-names></name> <etal/></person-group>. <article-title>Epidemiologic study of major complications in adolescent and adult patients with thalassemia in northeastern Thailand: the E-SAAN study phase I</article-title>. <source>Hematology</source>. (<year>2018</year>) <volume>23</volume>:<fpage>55</fpage>&#x2013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1080/10245332.2017.1358845</pub-id>, <pub-id pub-id-type="pmid">28759343</pub-id></mixed-citation></ref>
<ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>T</given-names></name></person-group>. <article-title>Iron and infection</article-title>. <source>Int J Hematol</source>. (<year>2018</year>) <volume>107</volume>:<fpage>7</fpage>&#x2013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12185-017-2366-2</pub-id>, <pub-id pub-id-type="pmid">29147843</pub-id></mixed-citation></ref>
<ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieracci</surname><given-names>FM</given-names></name> <name><surname>Barie</surname><given-names>PS</given-names></name></person-group>. <article-title>Iron and the risk of infection</article-title>. <source>Surg Infect</source>. (<year>2005</year>) <volume>6</volume>:<fpage>S41</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1089/sur.2005.6.s1-41</pub-id></mixed-citation></ref>
<ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>JK</given-names></name> <name><surname>Wang</surname><given-names>SC</given-names></name> <name><surname>Ho</surname><given-names>LW</given-names></name> <name><surname>Huang</surname><given-names>SW</given-names></name> <name><surname>Chang</surname><given-names>SH</given-names></name> <name><surname>Yang</surname><given-names>RC</given-names></name> <etal/></person-group>. <article-title>Chronic iron overload results in impaired bacterial killing of THP-1 derived macrophage through the inhibition of lysosomal acidification</article-title>. <source>PLoS One</source>. (<year>2016</year>) <volume>11</volume>:<fpage>e0156713</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0156713</pub-id>, <pub-id pub-id-type="pmid">27244448</pub-id></mixed-citation></ref>
<ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vento</surname><given-names>S</given-names></name> <name><surname>Cainelli</surname><given-names>F</given-names></name> <name><surname>Cesario</surname><given-names>F</given-names></name></person-group>. <article-title>Infections and thalassaemia</article-title>. <source>Lancet Infect Dis</source>. (<year>2006</year>) <volume>6</volume>:<fpage>226</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(06)70437-6</pub-id>, <pub-id pub-id-type="pmid">16554247</pub-id></mixed-citation></ref>
<ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanachiwanawin</surname><given-names>W</given-names></name></person-group>. <article-title>Infections in E-beta thalassemia</article-title>. <source>J Pediatr Hematol Oncol</source>. (<year>2000</year>) <volume>22</volume>:<fpage>581</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00043426-200011000-00027</pub-id>, <pub-id pub-id-type="pmid">11132234</pub-id></mixed-citation></ref>
<ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>GC</given-names></name> <name><surname>Chan</surname><given-names>S</given-names></name> <name><surname>Ho</surname><given-names>PL</given-names></name> <name><surname>Ha</surname><given-names>SY</given-names></name></person-group>. <article-title>Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of <italic>Klebsiella pneumoniae</italic> and <italic>Aeromonas hydrophila</italic> isolated from transfusion-dependent thalassemia patients</article-title>. <source>Hemoglobin</source>. (<year>2009</year>) <volume>33</volume>:<fpage>352</fpage>&#x2013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.3109/03630260903211888</pub-id></mixed-citation></ref>
<ref id="ref10"><label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Taher</surname><given-names>AT</given-names></name> <name><surname>Farmakis</surname><given-names>D</given-names></name> <name><surname>Porter</surname><given-names>JB</given-names></name> <name><surname>Cappellini</surname><given-names>MD</given-names></name> <name><surname>Musallam</surname><given-names>KM</given-names></name></person-group>. <source>Guidelines for the Management of Transfusion Dependent &#x03B2;-Thalassaemia (TDT)</source>. <edition>5th</edition> ed. <publisher-loc>Nicosia, (CY)</publisher-loc>: <publisher-name>Thalassaemia International Federation</publisher-name> (<year>2025</year>).</mixed-citation></ref>
<ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricerca</surname><given-names>BM</given-names></name> <name><surname>Di Girolamo</surname><given-names>A</given-names></name> <name><surname>Rund</surname><given-names>D</given-names></name></person-group>. <article-title>Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications</article-title>. <source>Mediterr J Hematol Infect Dis</source>. (<year>2009</year>) <volume>1</volume>:<fpage>e2009028</fpage>. doi: <pub-id pub-id-type="doi">10.4084/MJHID.2009.028</pub-id>, <pub-id pub-id-type="pmid">21415996</pub-id></mixed-citation></ref>
<ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gluba-Brzozka</surname><given-names>A</given-names></name> <name><surname>Franczyk</surname><given-names>B</given-names></name> <name><surname>Rysz-Gorzynska</surname><given-names>M</given-names></name> <name><surname>Rokicki</surname><given-names>R</given-names></name> <name><surname>Koziarska-Rosciszewska</surname><given-names>M</given-names></name> <name><surname>Rysz</surname><given-names>J</given-names></name></person-group>. <article-title>Pathomechanisms of immunological disturbances in beta-thalassemia</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>22</volume>:<fpage>9677</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms22189677</pub-id></mixed-citation></ref>
<ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haque</surname><given-names>M</given-names></name> <name><surname>Sartelli</surname><given-names>M</given-names></name> <name><surname>McKimm</surname><given-names>J</given-names></name> <name><surname>Abu Bakar</surname><given-names>M</given-names></name></person-group>. <article-title>Health care-associated infections&#x2014;an overview</article-title>. <source>Infect Drug Resist</source>. (<year>2018</year>) <volume>11</volume>:<fpage>2321</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S177247</pub-id>, <pub-id pub-id-type="pmid">30532565</pub-id></mixed-citation></ref>
<ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teawtrakul</surname><given-names>N</given-names></name> <name><surname>Jetsrisuparb</surname><given-names>A</given-names></name> <name><surname>Sirijerachai</surname><given-names>C</given-names></name> <name><surname>Chansung</surname><given-names>K</given-names></name> <name><surname>Wanitpongpun</surname><given-names>C</given-names></name></person-group>. <article-title>Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors</article-title>. <source>Int J Infect Dis</source>. (<year>2015</year>) <volume>39</volume>:<fpage>53</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2015.09.001</pub-id>, <pub-id pub-id-type="pmid">26358855</pub-id></mixed-citation></ref>
<ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>CT</given-names></name> <name><surname>Tsai</surname><given-names>CH</given-names></name> <name><surname>Wang</surname><given-names>JH</given-names></name> <name><surname>Chiu</surname><given-names>CF</given-names></name> <name><surname>Chow</surname><given-names>KC</given-names></name></person-group>. <article-title>Bacterial infection in patients with transfusion-dependent beta-thalassemia in Central Taiwan</article-title>. <source>Acta Paediatr Taiwan</source>. (<year>2000</year>) <volume>41</volume>:<fpage>318</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="pmid">11198938</pub-id></mixed-citation></ref>
<ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SC</given-names></name> <name><surname>Lin</surname><given-names>KH</given-names></name> <name><surname>Chern</surname><given-names>JP</given-names></name> <name><surname>Lu</surname><given-names>MY</given-names></name> <name><surname>Jou</surname><given-names>ST</given-names></name> <name><surname>Lin</surname><given-names>DT</given-names></name> <etal/></person-group>. <article-title>Severe bacterial infection in transfusion-dependent patients with thalassemia major</article-title>. <source>Clin Infect Dis</source>. (<year>2003</year>) <volume>37</volume>:<fpage>984</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1086/378062</pub-id>, <pub-id pub-id-type="pmid">13130412</pub-id></mixed-citation></ref>
<ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name></person-group>. <article-title>The National Early Warning Score: from concept to NHS implementation</article-title>. <source>Clin Med (Lond)</source>. (<year>2022</year>) <volume>22</volume>:<fpage>499</fpage>&#x2013;<lpage>505</lpage>. doi: <pub-id pub-id-type="doi">10.7861/clinmed.2022-news-concept</pub-id>, <pub-id pub-id-type="pmid">36427887</pub-id></mixed-citation></ref>
<ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piyajaroenkij</surname><given-names>T</given-names></name> <name><surname>Tantiworawit</surname><given-names>A</given-names></name> <name><surname>Khikhuntod</surname><given-names>J</given-names></name> <name><surname>Piriyakhuntorn</surname><given-names>P</given-names></name> <name><surname>Rattanathammethee</surname><given-names>T</given-names></name> <name><surname>Hantrakool</surname><given-names>S</given-names></name> <etal/></person-group>. <article-title>Alteration of monocyte subsets and their functions in thalassemia patients</article-title>. <source>Int J Hematol</source>. (<year>2023</year>) <volume>117</volume>:<fpage>188</fpage>&#x2013;<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12185-022-03484-9</pub-id>, <pub-id pub-id-type="pmid">36323999</pub-id></mixed-citation></ref>
<ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinjoy</surname><given-names>S</given-names></name> <name><surname>Hantrakun</surname><given-names>V</given-names></name> <name><surname>Kongyu</surname><given-names>S</given-names></name> <name><surname>Kaewrakmuk</surname><given-names>J</given-names></name> <name><surname>Wangrangsimakul</surname><given-names>T</given-names></name> <name><surname>Jitsuronk</surname><given-names>S</given-names></name> <etal/></person-group>. <article-title>Melioidosis in Thailand: present and future</article-title>. <source>Trop Med Infect Dis</source>. (<year>2018</year>) <volume>3</volume>:<fpage>38</fpage>. doi: <pub-id pub-id-type="doi">10.3390/tropicalmed3020038</pub-id>, <pub-id pub-id-type="pmid">29725623</pub-id></mixed-citation></ref>
<ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonejuie</surname><given-names>P</given-names></name> <name><surname>Wilantho</surname><given-names>A</given-names></name> <name><surname>McDonald</surname><given-names>D</given-names></name> <name><surname>Htoo</surname><given-names>HH</given-names></name> <name><surname>Chalerm</surname><given-names>J</given-names></name> <name><surname>Tripathi</surname><given-names>A</given-names></name> <etal/></person-group>. <article-title>Differential gut microbiota composition in &#x03B2;-thalassemia patients and its correlation with iron overload</article-title>. <source>Sci Rep</source>. (<year>2024</year>) <volume>14</volume>:<fpage>23858</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-024-75456-4</pub-id>, <pub-id pub-id-type="pmid">39394230</pub-id></mixed-citation></ref>
<ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>BH</given-names></name> <name><surname>Ha</surname><given-names>SY</given-names></name> <name><surname>Chan</surname><given-names>GC</given-names></name> <name><surname>Chiang</surname><given-names>A</given-names></name> <name><surname>Lee</surname><given-names>TL</given-names></name> <name><surname>Ho</surname><given-names>HK</given-names></name> <etal/></person-group>. <article-title>Klebsiella infection in patients with thalassemia</article-title>. <source>Clin Infect Dis</source>. (<year>2003</year>) <volume>36</volume>:<fpage>575</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1086/367656</pub-id>, <pub-id pub-id-type="pmid">12594637</pub-id></mixed-citation></ref>
<ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgna-Pignatti</surname><given-names>C</given-names></name> <name><surname>Rugolotto</surname><given-names>S</given-names></name> <name><surname>De Stefano</surname><given-names>P</given-names></name> <name><surname>Zhao</surname><given-names>H</given-names></name> <name><surname>Cappellini</surname><given-names>MD</given-names></name> <name><surname>Del Vecchio</surname><given-names>GC</given-names></name> <etal/></person-group>. <article-title>Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine</article-title>. <source>Haematologica</source>. (<year>2004</year>) <volume>89</volume>:<fpage>1187</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="pmid">15477202</pub-id></mixed-citation></ref>
<ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jongprasartsuk</surname><given-names>W</given-names></name></person-group>. <article-title>Deep neck infections: a study of 127 cases in Nan Hospital</article-title>. <source>Lampang Med J</source>. (<year>2022</year>) <volume>32</volume>:<fpage>42</fpage>&#x2013;<lpage>50</lpage>.</mixed-citation></ref>
<ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wangthanakorn</surname><given-names>S</given-names></name></person-group>. <article-title>Factor related to severe deep neck infections: retrospective study in Udonthani</article-title>. <source>Thai J Otolaryngol Head Neck Surg</source>. (<year>2021</year>) <volume>22</volume>:<fpage>3</fpage>&#x2013;<lpage>19</lpage>.</mixed-citation></ref>
<ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madhok</surname><given-names>S</given-names></name></person-group>. <article-title>Dental considerations in Thalassemic patients</article-title>. <source>J Dent Med Sci</source>. (<year>2014</year>) <volume>13</volume>:<fpage>57</fpage>&#x2013;<lpage>62</lpage>.</mixed-citation></ref>
<ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abuga</surname><given-names>KM</given-names></name> <name><surname>Muriuki</surname><given-names>JM</given-names></name> <name><surname>Williams</surname><given-names>TN</given-names></name> <name><surname>Atkinson</surname><given-names>SH</given-names></name></person-group>. <article-title>How severe anaemia might influence the risk of invasive bacterial infections in African children</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>:<fpage>6976</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21186976</pub-id>, <pub-id pub-id-type="pmid">32972031</pub-id></mixed-citation></ref>
<ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orf</surname><given-names>K</given-names></name> <name><surname>Cunnington</surname><given-names>AJ</given-names></name></person-group>. <article-title>Infection-related hemolysis and susceptibility to gram-negative bacterial co-infection</article-title>. <source>Front Microbiol</source>. (<year>2015</year>) <volume>6</volume>:<fpage>666</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2015.00666</pub-id>, <pub-id pub-id-type="pmid">26175727</pub-id></mixed-citation></ref>
<ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>DB</given-names></name></person-group>. <article-title>Postsplenectomy sepsis</article-title>. <source>Perspect Pediatr Pathol</source>. (<year>1973</year>) <volume>1</volume>:<fpage>285</fpage>&#x2013;<lpage>311</lpage>.</mixed-citation></ref>
<ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakran</surname><given-names>W</given-names></name> <name><surname>Levin</surname><given-names>C</given-names></name> <name><surname>Kenes</surname><given-names>Y</given-names></name> <name><surname>Colodner</surname><given-names>R</given-names></name> <name><surname>Koren</surname><given-names>A</given-names></name></person-group>. <article-title>Clinical spectrum of serious bacterial infections among splenectomized patients with hemoglobinopathies in Israel: a 37-year follow-up study</article-title>. <source>Infection</source>. (<year>2012</year>) <volume>40</volume>:<fpage>35</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s15010-011-0178-5</pub-id>, <pub-id pub-id-type="pmid">21866338</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0002">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1961970/overview">Maria Stefania Infante</ext-link>, Hospital Universitario Infanta Leonor, Spain</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0003">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2028705/overview">Wulandewi Marhaeni</ext-link>, Universitas Lambung Mangkurat, Indonesia</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3178697/overview">Afshan Shirkavand</ext-link>, Tehran University of Medical Sciences, Iran</p>
</fn>
</fn-group>
</back>
</article>